Schizophrenia Research
Volume 112, Issue 1 , Pages 80-85 , July 2009

CSF 5-HIAA, attempted suicide and suicide risk in schizophrenia spectrum psychosis

Received 5 February 2009 ,Revised 6 April 2009 ,Accepted 6 April 2009.

References 

  1. Ågren H. Life at risk: markers of suicidality in depression. Psychiatr. Dev. 1983;1(1):87–103
  2. Ågren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ. Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J. Psychiatr. Res. 1986;20(3):175–193
  3. Arango V, Underwood MD, Mann JJ. Alterations in monoamine receptors in the brain of suicide victims. J. Clin. Psychopharmacol. 1992;12(2 Suppl):8S–12S
  4. Arango V, Underwood MD, Mann JJ. Serotonin brain circuits involved in major depression and suicide. Prog. Brain Res. 2002;136:443–453
  5. Åsberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann. N. Y. Acad. Sci. 1997;836:158–181
  6. Åsberg M, Träskman L, Thoren P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor?. Arch. Gen. Psychiatry. 1976;33(10):1193–1197
  7. Banki CM, Arato M, Papp Z, Kurcz M. Biochemical markers in suicidal patients. Investigations with cerebrospinal fluid amine metabolites and neuroendocrine tests. J. Affect. Disord. 1984;6(3–4):341–350
  8. Banki CM, Arato M, Kilts CD. Aminergic studies and cerebrospinal fluid cations in suicide. Ann. N. Y. Acad. Sci. 1986;487:221–230
  9. Bjerkenstedt L, Gullberg B, Härnryd C, Sedvall G. Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene. Arch. Psychiatr. Nervenkr. 1977;224(2):107–118
  10. Carlborg A, Jokinen J, Jönsson EG, Nordström AL, Nordström P. Long-term suicide risk in schizophrenia spectrum psychoses: survival analysis by gender. Arch. Suicide Res. 2008;12(4):347–351
  11. Cohen S, Lavelle J, Rich CL, Bromet E. Rates and correlates of suicide attempts in first-admission psychotic patients. Acta Psychiatr. Scand. 1994;90(3):167–171
  12. Cooper SJ, Kelly CB, King DJ. 5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behaviour in schizophrenia. Lancet. 1992;340(8825):940–941
  13. Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am. J. Psychiatry. 1985;142(4):499–501
  14. Ekholm B, Ekholm A, Adolfsson R, Vares M, Ösby U, Sedvall GC, et al. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord. J. Psychiatry. 2005;59(6):457–464
  15. Engström G, Alling C, Blennow K, Regnell G, Träskman-Bendz L. Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur. Neuropsychopharmacol. 1999;9(5):399–405
  16. Gottfries CG, Gottfries I, Johansson B, Olsson R, Persson T, Roos BE, et al. Acid monoamine metabolites in human cerebrospinal fluid and their relations to age and sex. Neuropharmacology. 1971;10(6):665–672
  17. Härnryd C, Bjerkenstedt L, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA. Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr. Scand. Suppl. 1984;311:75–92
  18. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry. 1997;170:205–228
  19. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br. J. Psychiatry. 2005;187:9–20
  20. Heilä H, Isometsä ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lönnqvist JK. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J. Clin. Psychiatry. 1999;60(3):200–208
  21. Jokinen J, Nordström AL, Nordström P. The relationship between CSF HVA/5-HIAA ratio and suicide intent in suicide attempters. Arch. Suicide Res. 2007;11(2):187–192
  22. Lemus CZ, Lieberman JA, Johns CA, Pollack S, Bookstein P, Cooper TB. CSF 5-hydroxyindoleacetic acid levels and suicide attempts in schizophrenia. Biol. Psychiatry. 1990;27(8):926–929
  23. Lester D. The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiatry. 1995;28(2):45–50
  24. Mann JJ. Neurobiology of suicidal behaviour. Nat. Rev. Neurosci. 2003;4(10):819–828
  25. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am. J. Psychiatry. 1999;156(2):181–189
  26. Mann JJ, Currier D, Stanley B, Oquendo MA, Amsel LV, Ellis SP. Can biological tests assist prediction of suicide in mood disorders?. Int. J. Neuropsychopharmacol. 2006;9(4):465–474
  27. McGirr A, Tousignant M, Routhier D, Pouliot L, Chawky N, Margolese HC, et al. Risk factors for completed suicide in schizophrenia and other chronic psychotic disorders: a case–control study. Schizophr. Res. 2006;84(1):132–143
  28. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry. 2003;60(1):82–91
  29. Modestin J, Dal Pian D, Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. J. Clin. Psychiatry. 2005;66(4):534–538
  30. Ninan PT, van Kammen DP, Scheinin M, Linnoila M, Bunney WE, Goodwin FK. CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. Am. J. Psychiatry. 1984;141(4):566–569
  31. Nordström P, Samuelsson M, Åsberg M, Träskman-Bendz L, Åberg-Wistedt A, Nordin C, et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life-threat. Behav. 1994;24(1):1–9
  32. Nordström AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am. J. Psychiatry. 1995;152(10):1444–1449
  33. Pickar D, Roy A, Breier A, Doran A, Wolkowitz O, Colison J, et al. Suicide and aggression in schizophrenia. Neurobiologic correlates. Ann. N. Y. Acad. Sci. 1986;487:189–196
  34. Placidi GP, Oquendo MA, Malone KM, Huang YY, Ellis SP, Mann JJ. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol. Psychiatry. 2001;50(10):783–791
  35. Roggenbach J, Muller-Oerlinghausen B, Franke L. Suicidality, impulsivity and aggression—is there a link to 5HIAA concentration in the cerebrospinal fluid?. Psychiatry Res. 2002;113(1–2):193–206
  36. Roy A, Ninan P, Mazonson A, Pickar D, Van Kammen D, Linnoila M, et al. CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Psychol. Med. 1985;15(2):335–340
  37. Roy A, Ågren H, Pickar D, Linnoila M, Doran AR, Cutler NR, et al. Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression. Am. J. Psychiatry. 1986;143(12):1539–1545
  38. Roy-Byrne P, Post RM, Rubinow DR, Linnoila M, Savard R, Davis D. CSF 5HIAA and personal and family history of suicide in affectively ill patients: a negative study. Psychiatry Res. 1983;10(4):263–274
  39. Sedvall GC, Wode-Helgodt B. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients. Arch. Gen. Psychiatry. 1980;37(10):1113–1116
  40. Sher L, Carballo JJ, Grunebaum MF, Burke AK, Zalsman G, Huang YY, et al. A prospective study of the association of cerebrospinal fluid monoamine metabolite levels with lethality of suicide attempts in patients with bipolar disorder. Bipolar Disord. 2006;8(5 Pt 2):543–550
  41. Sinclair JM, Mullee MA, King EA, Baldwin DS. Suicide in schizophrenia: a retrospective case–control study of 51 suicides. Schizophr. Bull. 2004;30(4):803–811
  42. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet. 1983;1(8318):214–216
  43. Stanley M, Virgilio J, Gershon S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science. 1982;216(4552):1337–1339
  44. Swahn CG, Sandgarde B, Wiesel FA, Sedvall G. Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method. Psychopharmacology (Berl). 1976;48(2):147–153
  45. Tidemalm D, Langström N, Lichtenstein P, Runeson B. Risk of suicide after suicide attempt according to coexisting psychiatric disorder: Swedish cohort study with long term follow-up. BMJ. 2008;337:a2205
  46. Träskman L, Åsberg M, Bertilsson L, Sjöstrand L. Monoamine metabolites in CSF and suicidal behavior. Arch. Gen. Psychiatry. 1981;38(6):631–636
  47. van Praag HM. CSF 5-HIAA and suicide in non-depressed schizophrenics. Lancet. 1983;2(8356):977–978
  48. Vares M, Ekholm A, Sedvall GC, Hall H, Jönsson EG. Characterization of patients with schizophrenia and related psychoses: evaluation of different diagnostic procedures. Psychopathology. 2006;39(6):286–295
  49. Wode-Helgodt B, Sedvall G. Correlations between height of subject and concentrations of monoamine metabolites in cerebrospinal fluid from psychotic men and women. Commun. Psychopharmacol. 1978;2(2):177–183
  50. Wode-Helgodt B, Fyrö B, Gullberg B, Sedvall G. Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Acta Psychiatr. Scand. 1977;56(2):129–142

PII: S0920-9964(09)00171-6

doi: 10.1016/j.schres.2009.04.006

Schizophrenia Research
Volume 112, Issue 1 , Pages 80-85 , July 2009

Article Tools

* Image Usage & Resolution